Cargando…

P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

Detalles Bibliográficos
Autores principales:	Mol, Isha, Hu, Yannan, Cappelleri, Joseph, Chu, Haitao, Aydin, Didem, Hlavacek, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431132/ http://dx.doi.org/10.1097/01.HS9.0000970636.73112.6c

Ejemplares similares

Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma
por: Rais, Taruba, et al.
Publicado: (2023)

P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)
por: Costa, Luciano, et al.
Publicado: (2023)

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
por: Bahlis, Nizar J., et al.
Publicado: (2023)

Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case
por: Mutlu, Yasa Gul, et al.
Publicado: (2023)

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
por: Lesokhin, Alexander M., et al.
Publicado: (2023)

PB2100: REAL-WORLD TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A RETROSPECTIVE CHART STUDY
por: Guillaume, Xavier, et al.
Publicado: (2023)

DEX, Delirium and Dilemma
por: Magoon, Rohan, et al.
Publicado: (2023)

P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Touzeau, Cyrille, et al.
Publicado: (2023)

PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Fonseca, R., et al.
Publicado: (2022)

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Leleu, Xavier, et al.
Publicado: (2023)

Expression of NEAT1 can be used as a predictor for Dex resistance in multiple myeloma patients
por: Ren, Yuyue, et al.
Publicado: (2023)

La statue de sel /
por: Memmi, Albert
Publicado: (1966)

Determinants of Bacteriophage 933W Repressor DNA Binding Specificity
por: Bullwinkle, Tammy J., et al.
Publicado: (2012)

Application of F 933 as a Routine Test in Sustained Hypertension
por: Gibbs, Donald F.
Publicado: (1952)

Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)
por: Kivitz, Alan, et al.
Publicado: (2023)

P924: TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A REAL-WORLD OBSERVATIONAL CHART REVIEW STUDY
por: Goyal, Ravi K, et al.
Publicado: (2023)

Expression of the selenoprotein S (SELS) gene in subcutaneous adipose tissue and SELS genotype are associated with metabolic risk factors
por: Olsson, Maja, et al.
Publicado: (2011)

P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
por: Schjesvold, F, et al.
Publicado: (2023)

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Dalovisio, A., et al.
Publicado: (2022)

PB2131: MAGNETISMM-7: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF ELRANATAMAB VERSUS LENALIDOMIDE IN POST-TRANSPLANT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Manteca, Maria Victoria Mateos, et al.
Publicado: (2023)

etymologia: Brucella [broo-sel′ə]
Publicado: (2008)

Relevance of Bacteriophage 933W in the Development of Hemolytic Uremic Syndrome (HUS)
por: Del Cogliano, Manuel E., et al.
Publicado: (2018)

SUN-933 Lactic Acidosis as a Rare and Unusual Presentation of Pheochromocytoma
por: Mohammad, Nazar, et al.
Publicado: (2020)

933. Incidence and Risk Factors for Cytomegalovirus Infection in Intestinal Transplant Recipients
por: Fernandez, Anmary A, et al.
Publicado: (2021)

Synergistic Effect of Perineural Dexamethasone and Dexmedetomidine (Dex-Dex) Prolong Analgesic Effect of a Preoperative Interscalene Block
por: Noor, Nazir A, et al.
Publicado: (2020)

A current of 31.933 A in ring 1 at 31.4 GeV/c, Run 933, 26/31 GeV/c, 28/04/78
por: Fischer, C, et al.
Publicado: (1978)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Grosicki, Sebastian, et al.
Publicado: (2023)

Intravitreal DEX Implant for the Treatment of Diabetic Macular Edema: A Review of National Consensus
por: Spinetta, Roberta, et al.
Publicado: (2023)

Synergistic Effect of Perineural Dexamethasone and Dexmedetomidine (Dex-Dex) in Extending the Analgesic Duration of Pectoral Type I and II Blocks
por: Zusman, Robert P, et al.
Publicado: (2020)

Correction: Synergistic Effect of Perineural Dexamethasone and Dexmedetomidine (Dex-Dex) Prolong Analgesic Effect of a Preoperative Interscalene Block
por: Noor, Nazir A, et al.
Publicado: (2020)

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A
por: Rodríguez-Otero, Paula, et al.
Publicado: (2023)

User manual for the VMOD-SEL plug-in card
por: Schipper, J
Publicado: (1996)

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
por: Katodritou, Eirini, et al.
Publicado: (2018)

P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
por: Manier, Salomon, et al.
Publicado: (2023)

933. Serum Albumin Is Associated With Higher Inflammation and Carotid Atherosclerosis in Treated HIV Infection
por: Dirajlal-Fargo, Sahera, et al.
Publicado: (2018)

L'esprit de sel: science, culture, politique
por: Lévy-Leblond, Jean-Marc
Publicado: (1984)

Energy Dependence of Tungsten-Dominated SEL Cross Sections
por: Alia, R G, et al.
Publicado: (2014)

SEL Hardness Assurance in a Mixed Radiation Field
por: Alia, Ruben Garcia, et al.
Publicado: (2015)

SEL Hardness Assurance in a Mixed Radiation Field
por: Garcia Alia, Ruben, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b8brhost1jt42ab9ubtu31b0f5